The Supreme Court on Monday rejected appeals from pharmaceutical companies challenging the federal government's authority to negotiate drug prices under Medicare, allowing the program created by the 2022 Inflation Reduction Act to continue unimpeded.
The justices did not comment in leaving in place rulings from the Third Circuit Court of Appeals that dismissed the manufacturers' claims. The decision marks a significant legal victory for the Biden-era healthcare policy, which was signed into law before President Donald Trump took office but has been embraced by his administration.
What the Right Is Saying
Republican critics of the Inflation Reduction Act reiterated their opposition to what they characterize as government price-setting. While acknowledging the Supreme Court's decision, conservative commentators argued the policy amounts to government interference in free markets.
"This is a continuation of a flawed approach that caps innovation incentives," said Senator Thom Tillis of North Carolina. "We should be finding market-based solutions that lower costs without government bureaucrats deciding drug prices."
The pharmaceutical industry maintained its position that reducing drug costs would come from addressing insurer and pharmacy benefit manager practices rather than direct price negotiations with the federal government.
What the Left Is Saying
Progressive Democrats and healthcare advocates praised the ruling as a long-overdue affirmation of government authority to address prescription drug costs for seniors. The program represents years of advocacy from progressive groups that pushed for direct federal negotiation power, an effort that stalled repeatedly in Congress before being included in the IRA.
"Big pharma's attempt to kill Medicare drug pricing failed. Seniors are winning," said Senator John Fetterman of Pennsylvania on social media. He noted that his state has one of the highest concentrations of Medicare beneficiaries who stand to benefit from lower prices on expensive medications.
AARP, which represents Americans over 50, called the Supreme Court's inaction "a victory for Medicare patients across the country" and noted that negotiated prices have already begun reducing out-of-pocket costs for enrollees in the program.
What the Numbers Show
The Inflation Reduction Act required the Centers for Medicare and Medicaid Services to negotiate prices for high-cost drugs covered by Medicare on an annual basis. The first round of negotiated prices took effect in 2026, covering 10 drugs initially.
According to CMS data, the program has expanded to cover 25 prescription medications, including popular GLP-1 treatments such as Ozempic, Rybelsus, and Wegovy used for diabetes and weight management. In January, the Trump administration announced a third round of negotiations that would bring total covered drugs to 40.
The Congressional Budget Office previously estimated the negotiation program could save Medicare approximately $102 billion over ten years. Pharmaceutical manufacturers have disputed these projections, arguing price controls reduce research and development investment.
The Bottom Line
With appeals exhausted at the federal level, stopping the Medicare drug negotiation program now requires an act of Congress. The statute does not include a termination date, meaning the policy will continue unless lawmakers pass legislation to repeal it or courts rule differently in separate pending challenges.
The Trump administration's embrace of the negotiation authority marks an unusual position for Republican leadership, which largely opposed the Inflation Reduction Act. Industry observers suggest pharmaceutical companies may shift strategy toward influencing future legislative debates rather than pursuing additional litigation.